帕金森病中α-突触核蛋白在多组织和生物体液中的体内分布
S4研究为6中心横断面观察性研究,纳入59例帕金森病(PD)患者和21名健康对照(HC),检测皮肤、结肠、下颌下腺(SMG)活检及脑脊液(CSF)、唾液、血液中的α-突触核蛋白。结果显示PD患者CSF总α-突触核蛋白低于HC,敏感性87.0%、特异性63.2%;SMG和皮肤免疫反应性对PD诊断特异性高(92.9%和100%)但敏感性低(56.1%和24.1%)。不同组织与生物体液间的α-突触核蛋白测量值无显著关联。
要点
- PD患者CSF总α-突触核蛋白低于HC,但特异性仅63.2%。
- SMG和皮肤α-突触核蛋白免疫反应性对PD诊断特异性高但敏感性低。
- 同一受试者不同组织与生物体液间α-突触核蛋白测量无显著关联。
核心结论
- S4研究证实PD患者CSF总α-突触核蛋白低于HC,但特异性低。
- 皮肤和SMG的α-突触核蛋白免疫反应性对PD特异但敏感性低。
- 未能在同一受试者中证明不同组织与生物体液间α-突触核蛋白测量的关联。
- 亟需更高准确度的病理性α-突触核蛋白测量方法。
研究设计与样本
- S4为6中心横断面观察性研究,纳入早期、中期或晚期PD患者与HC。
- 收集皮肤、结肠、下颌下腺活检及CSF、唾液、血液样本。
- 组织切片用5C12单克隆抗体染色,由对诊断不知情的神经病理学家判读。
- 生物体液总α-突触核蛋白用ELISA定量。
主要发现
- 最终队列包括59例PD患者和21名HC。
- PD患者CSF α-突触核蛋白低于HC,敏感性/特异性分别为87.0%/63.2%。
- α-突触核蛋白免疫反应性对PD诊断的敏感性:SMG 56.1%、皮肤24.1%;特异性:SMG 92.9%、皮肤100%。
- 同一受试者不同α-突触核蛋白测量指标间无显著关系。
关键数值与推荐
- CSF α-突触核蛋白诊断PD的敏感性87.0%、特异性63.2%。
- SMG α-突触核蛋白免疫反应性诊断PD的敏感性56.1%、特异性92.9%。
- 皮肤α-突触核蛋白免疫反应性诊断PD的敏感性24.1%、特异性100%。
临床怎么用
- CSF总α-突触核蛋白不宜单独用于区分PD与HC,因特异性低。
- SMG和皮肤α-突触核蛋白染色可作为特异性辅助标志,但阴性结果不能排除PD。
- 临床解读α-突触核蛋白标志物时需结合组织类型与检测方法。
局限性
- 样本量有限(59例PD和21名HC),可能影响统计效能。
- 横断面设计无法评估α-突触核蛋白分布随疾病进展的变化。
- 研究未能在同一受试者中证明不同组织与生物体液测量的关联。
- 证据等级为Class III,提示CSF总α-突触核蛋白不能准确区分PD与HC。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Systemic Synuclein Sampling Study (S4) measured α-synuclein in multiple tissues and biofluids within the same patients with Parkinson disease (PD) vs healthy controls (HCs). METHODS: S4 was a 6-site cross-sectional observational study of participants with early, moderate, or advanced PD and HCs. Motor and nonmotor measures and dopamine transporter SPECT were obtained. Biopsies of skin, colon, submandibular gland (SMG), CSF, saliva, and blood were collected. Tissue biopsy sections were stained with 5C12 monoclonal antibody against pathologic α-synuclein; digital images were interpreted by neuropathologists blinded to diagnosis. Biofluid total α-synuclein was quantified using ELISA. RESULTS: The final cohort included 59 patients with PD and 21 HCs. CSF α-synuclein was lower in patients with PD vs HCs; sensitivity/specificity of CSF α-synuclein for PD diagnosis was 87.0%/63.2%, respectively. Sensitivity of α-synuclein immunoreactivity for PD diagnosis was 56.1% for SMG and 24.1% for skin; specificity was 92.9% and 100%, respectively. There were no significant relationships between different measures of α-synuclein within participants. CONCLUSIONS: S4 confirms lower total α-synuclein levels in CSF in patients with PD compared to HCs, but specificity is low. In contrast, α-synuclein immunoreactivity in skin and SMG is specific for PD but sensitivity is low. Relationships within participants across different tissues and biofluids could not be demonstrated. Measures of pathologic forms of α-synuclein with higher accuracy are critically needed. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that total CSF α-synuclein does not accurately distinguish patients with PD from HCs, and that monoclonal antibody staining for SMG and skin total α-synuclein is specific but not sensitive for PD diagnosis.
引用
- Chahine LM, Beach TG, Brumm MC, et al. In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology. 2020. PMID: 32747521. doi:10.1212/WNL.0000000000010404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。